Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Lilly yesterday announced the next component in the ‘beyond the pill’ strategy it is constructing for diabetes, a new alliance with digital health company Rimidi.

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

There is also a risk of hypoglycemia or low blood sugar, especially for people taking insulin or medications such as sulfonylureas. This risk is lower with other diabetes medications, but it still ...

Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Has there ever been a better time to read “Blood on Satan’s Claw ... Mark Dery is a cultural critic and the author of four books, most recently the biography “Born to Be Posthumous ...

As you age, your risk for higher blood sugar increases—which raises the risk of type 2 diabetes for adults in their 50s, 60s, and 70s. Using a chart of blood sugar levels by age can help you track ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...